The aim of this study was to determine survival and prognostic factors in unselected patients with metastatic castrate-resistant prostate cancer (mCRPC), who never received life-prolonging treatment.
ORLANDO, FL USA (UroToday.com) - Recurrence rates and survival rates are associated with PSA doubling time in patients following radical prostatectomy. Adam Gordon and colleagues, in this observational study, assessed PSA doubling time over time for geometric or linear progression. The authors reported that those who had geometric progression were treated as opposed to patients with linear progression who were just observed.
68Ga-PSMA Positron Emission Tomography/Computerized Tomography (PET/CT) has shown promising results for the detection of recurrent prostate cancer (RPCa). However, the diagnostic value of this method is yet to be validated.
The prognostic value of PSA kinetics in untreated prostate cancer (PCa) patients is debatable. We investigated the association between PSA doubling time (PSAdt), PSA velocity (PSAvel), and PSAvel risk count (PSAvRC) and PCa mortality in a cohort of patients with localised PCa managed on watchful waiting.
AIM - Physical activity after prostate cancer diagnosis has been shown to reduce the risk of disease progression. Here, we aimed to evaluate the effect of a 2-year home-based endurance training intervention on body composition, biomarkers levels, and prostate-specific antigen (PSA) doubling time as a surrogate end-point for progressing disease.
To examine the relationship between the extent of disease determined by [(68)Ga]PSMA-HBED-CC-PET/CT and the important clinical measures prostate-specific antigen (PSA), PSA doubling time (PSAdt) and Gleason score.
To examine the prognosis after BCR with and without salvage therapy, including radiation and/or androgen deprivation.
The study population consisted of 431 patients, all of whom underwent radical prostatectomy and developed BCR (PSA > 0.
Login to update email address, newsletter preferences and use bookmarks.